Beximco Pharmaceuticals Limited (AIM: BXP)
London
· Delayed Price · Currency is GBP · Price in GBX33.50
0.00 (0.00%)
Nov 22, 2024, 2:00 PM GMT+1
Beximco Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Revenue | 44,946 | 44,392 | 39,267 | 34,669 | 29,494 | 25,612 | Upgrade
|
| Revenue Growth (YoY) | 10.60% | 13.05% | 13.26% | 17.55% | 15.16% | 12.25% | Upgrade
|
| Cost of Revenue | 25,043 | 24,989 | 22,164 | 18,989 | 15,677 | 13,787 | Upgrade
|
| Gross Profit | 19,903 | 19,403 | 17,102 | 15,681 | 13,816 | 11,825 | Upgrade
|
| Selling, General & Admin | 11,366 | 11,112 | 10,200 | 9,101 | 7,470 | 6,451 | Upgrade
|
| Operating Expenses | 11,366 | 11,112 | 10,200 | 9,101 | 7,470 | 6,451 | Upgrade
|
| Operating Income | 8,537 | 8,291 | 6,902 | 6,580 | 6,346 | 5,374 | Upgrade
|
| Interest Expense | -1,102 | -1,121 | -1,242 | -925.6 | -805.87 | -983.2 | Upgrade
|
| Interest & Investment Income | 17.08 | 17.08 | 7.46 | 5.07 | 3.32 | 21.84 | Upgrade
|
| Currency Exchange Gain (Loss) | 8.9 | 8.9 | 66.94 | 50.12 | -3.72 | 13.2 | Upgrade
|
| Other Non Operating Income (Expenses) | 186.35 | 311.17 | 314.3 | 402.75 | 298.91 | 261.72 | Upgrade
|
| EBT Excluding Unusual Items | 7,648 | 7,507 | 6,049 | 6,112 | 5,839 | 4,687 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -57.3 | -18.21 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 16.38 | 16.38 | 13.82 | 12.62 | 3.96 | -33.8 | Upgrade
|
| Other Unusual Items | 2.4 | 2.4 | 6.1 | 619.47 | 552.99 | - | Upgrade
|
| Pretax Income | 7,666 | 7,525 | 6,069 | 6,687 | 6,378 | 4,653 | Upgrade
|
| Income Tax Expense | 1,675 | 1,659 | 1,544 | 1,688 | 1,212 | 1,109 | Upgrade
|
| Earnings From Continuing Operations | 5,991 | 5,867 | 4,524 | 4,999 | 5,166 | 3,544 | Upgrade
|
| Minority Interest in Earnings | -34.06 | -37.24 | 89.6 | 124.51 | -38.06 | -29.8 | Upgrade
|
| Net Income | 5,957 | 5,830 | 4,614 | 5,123 | 5,128 | 3,515 | Upgrade
|
| Net Income to Common | 5,957 | 5,830 | 4,614 | 5,123 | 5,128 | 3,515 | Upgrade
|
| Net Income Growth | 26.21% | 26.34% | -9.94% | -0.09% | 45.89% | 15.87% | Upgrade
|
| Shares Outstanding (Basic) | 446 | 446 | 446 | 446 | 446 | 446 | Upgrade
|
| Shares Outstanding (Diluted) | 446 | 446 | 446 | 446 | 446 | 446 | Upgrade
|
| Shares Change (YoY) | -0.05% | - | - | - | - | -0.00% | Upgrade
|
| EPS (Basic) | 13.36 | 13.07 | 10.34 | 11.48 | 11.49 | 7.88 | Upgrade
|
| EPS (Diluted) | 13.36 | 13.07 | 10.34 | 11.48 | 11.49 | 7.88 | Upgrade
|
| EPS Growth | 26.28% | 26.34% | -9.94% | -0.09% | 45.89% | 15.87% | Upgrade
|
| Free Cash Flow | 5,562 | 6,371 | 3,674 | 2,399 | 3,503 | 3,299 | Upgrade
|
| Free Cash Flow Per Share | 12.47 | 14.28 | 8.24 | 5.38 | 7.85 | 7.39 | Upgrade
|
| Dividend Per Share | - | 4.000 | 3.500 | 3.500 | 3.500 | 1.364 | Upgrade
|
| Dividend Growth | - | 14.29% | 0% | 0% | 156.67% | 0% | Upgrade
|
| Gross Margin | 44.28% | 43.71% | 43.55% | 45.23% | 46.85% | 46.17% | Upgrade
|
| Operating Margin | 18.99% | 18.68% | 17.58% | 18.98% | 21.52% | 20.98% | Upgrade
|
| Profit Margin | 13.25% | 13.13% | 11.75% | 14.78% | 17.39% | 13.72% | Upgrade
|
| Free Cash Flow Margin | 12.37% | 14.35% | 9.36% | 6.92% | 11.88% | 12.88% | Upgrade
|
| EBITDA | 10,149 | 9,974 | 8,962 | 8,247 | 7,460 | 6,488 | Upgrade
|
| EBITDA Margin | 22.58% | 22.47% | 22.82% | 23.79% | 25.29% | 25.33% | Upgrade
|
| D&A For EBITDA | 1,612 | 1,684 | 2,061 | 1,667 | 1,114 | 1,114 | Upgrade
|
| EBIT | 8,537 | 8,291 | 6,902 | 6,580 | 6,346 | 5,374 | Upgrade
|
| EBIT Margin | 18.99% | 18.68% | 17.58% | 18.98% | 21.52% | 20.98% | Upgrade
|
| Effective Tax Rate | 21.85% | 22.04% | 25.45% | 25.25% | 19.00% | 23.83% | Upgrade
|
| Advertising Expenses | - | 241.76 | 212.23 | 196.72 | 160 | 140.88 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.